Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PMS of Trazenta on the Long-term Use as Add-on Therapy

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01904383
First received: July 8, 2013
Last updated: September 16, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)